|
|
News Breaks | | | | January 4, 2013 | | 07:36 EDT |  | FOLD | Amicus Theraputics announces positive results from Phase 2 Chaperone-ERT study
Amicus Therapeutics announced positive preliminary results from all 4 dose cohorts in a Phase 2 study to evaluate the safety and pharmacokinetic, or PK, effects of the pharmacological chaperone AT2220 co-administered with enzyme replacement therapy, or ERT, for Pompe disease, Myozyme and Lumizyme. Myozyme and Lumizyme are the first and only approved treatments for Pompe disease. Based on the Study 010 results, Amicus expects to initiate a repeat-dose clinical study in Q3. | |
|
News For FOLD From The Last 14 Days Check below for free stories on FOLD the last two weeks. |
|
|
| May 9, 2013 | | 16:18 EDT |  | FOLD | Amicus Theraputics reports Q1 EPS (35c), consensus (33c)
 Subscribe for More Information | |
|
|
|
|
|
|
